Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-08-24	US$6.660	-0.52%	11,390
26-08-21	US$6.695	+1.06%	3,278
26-08-20	US$6.625	-3.43%	56,202
26-08-19	US$6.860	+5.38%	9,522
26-08-18	US$6.510	-1.96%	241,547

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq 16:00:00 2026-08-24 EDT			5-day change	1st Jan Change
6.660 ^USD	-0.52%		+1.06%	-45.59%

08-16	Neurothera Labs Inc. announced that it has received CAD 5.4 million in funding from SciSparc Ltd.	CI
08-05	SciSparc Ltd. Initiates Phase Iib Clinical Trial At Yale Child Study Center for Sci-110 for Tourette Syndrome	CI

Market Cap	3.82M 3.27M 3.06M 2.8M 5.28M 365M 5.34M 36.24M 14.09M 183M 14.33M 14.02M 607M	P/E 2024	-0.33x	P/E 2025	-0.12x
Enterprise Value	-407K -349K -327K -299K -564K -38.98M -570K -3.87M -1.5M -19.57M -1.53M -1.5M -64.77M	EV / Sales 2024	-551,308x	EV / Sales 2025	289,759x
Free-Float	100%	Yield 2024 *	-	Yield 2025	-

08-16	Neurothera Labs Inc. announced that it has received CAD 5.4 million in funding from SciSparc Ltd.	CI
08-05	SciSparc Ltd. Initiates Phase Iib Clinical Trial At Yale Child Study Center for Sci-110 for Tourette Syndrome	CI
07-29	Scisparc Ltd. Announces Establishment of Scientific Advisory Board	CI
06-29	Neurothera Labs Inc. announced that it expects to receive CAD 5.00175 million in funding from SciSparc Ltd.	CI
04-29	SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	SciSparc Ltd. Auditor Raises 'Going Concern' Doubt	CI
03-16	Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression Therapy	CI
03-16	Scisparc Neurothera Labs- Clearmind Medicine collaboration leads to patent application for depression therapy	RE
03-10	Clearmind Medicine Inc Announces Publication of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Metabolic Dysfunction-Associated Steatotic Liver Disease	CI
03-10	Top Premarket Decliners	MT
02-11	SciSparc Ltd. announced that it expects to receive $9 million in funding	CI
01-25	Neurothera Labs Inc. completed the acquisition of Portfolio of patents, trademarks, know-how of Xylo Technologies Ltd.	CI
01-13	SciSparc Subsidiary to Acquire Endoscopic Patents of Xylo Technologies in All-Stock Deal	MT

08-24	SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation	GL
08-19	SciSparc : Amendment to Annual Report by Foreign Issuer (Form 20-F/A)	PU
08-18	SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc's Stake Valued at Approximately C$30 Million	PU
08-18	SciSparc: Subsidiary NeuroThera Labs Completes C$5.4 Million Financing with SciSparc’s Stake Valued at Approximately C$30 Million	GL
08-12	SciSparc’s Subsidiary NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination	GL

SciSparc Ltd. Stock

Stocks

SPRC

IL0010951403

Pharmaceuticals

Valuation: SciSparc Ltd.

Chart: SciSparc Ltd.

Latest news : SciSparc Ltd.

Press Releases: SciSparc Ltd.

News in other languages: SciSparc Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: SciSparc Ltd.

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 day	-0.52%
1 week	+1.06%
Current month	-6.46%
1 month	+16.43%
3 months	+55.97%
6 months	+40.58%
Current year	-45.59%

1 week	6.4	7.6
1 month	4.76	11.51
Current year	2.98	15.79
1 year	2.98	80.1
3 years	2.98	2,687.56
5 years	0.49	41,769.08
10 years	0.49	41,769.08

Manager	Title	Age	Since
Oz Adler CEO	Chief Executive Officer	39	2022-01-09
Amitay Weiss CEO	Chief Executive Officer	62	2020-08-20
Adi Zuloff-Shani CTO	Chief Tech/Sci/R&D Officer	56	2016-02-07

Director	Title	Age	Since
Amitay Weiss CHM	Chairman	62	2022-01-09
Itschak Shrem CHM	Chairman	79	2025-09-20
Lior Vider BRD	Director/Board Member	50	2020-08-20

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCISPARC LTD.	-0.52%	+1.06%	-84.03%	-99.17%	3.84M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+0.40%	-1.04%	+16.34%	+69.97%	47.71B
OTSUKA HOLDINGS CO., LTD.	+0.12%	+1.50%	+51.38%	+122.20%	40.3B
CIPLA LIMITED	+0.40%	-0.83%	-9.73%	+16.84%	12.09B
ZYDUS LIFESCIENCES LIMITED	-1.45%	-2.77%	+11.63%	+71.04%	11.68B
KRKA, D. D.	+0.19%	+0.58%	+30.98%	+158.71%	9.19B
GEDEON RICHTER	+3.49%	+2.54%	+24.70%	+43.56%	7.57B
ONO PHARMACEUTICAL CO., LTD.	-0.16%	+0.58%	+47.14%	-11.83%	7.24B
GLENMARK PHARMACEUTICALS LIMITED	+3.14%	+3.12%	+23.40%	+215.25%	6.84B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-3.24%	-9.40%	-40.05%	+18.52%	5.42B
Average	+0.24%	-0.91%	+7.18%	+60.51%	14.8B
Weighted average by Cap.	+0.29%	-0.65%	+24.48%	+84.92%

	2024	2025
Net sales	1.31 1.12 1.05 0.96 1.81 125.03 1.83 12.4 4.82 62.76 4.9 4.8 207.73	0.86 0.73 0.69 0.63 1.18 81.95 1.2 8.13 3.16 41.13 3.21 3.14 136.15
Net income	-6.28M -5.39M -5.04M -4.61M -8.7M -602M -8.79M -59.65M -23.19M -302M -23.59M -23.08M -1B	-12.18M -10.44M -9.77M -8.93M -16.86M -1.17B -17.04M -116M -44.94M -585M -45.73M -44.73M -1.94B
Net Debt	-2.01M -1.72M -1.61M -1.47M -2.78M -193M -2.81M -19.09M -7.42M -96.63M -7.55M -7.39M -320M	-4.22M -3.62M -3.39M -3.1M -5.85M -404M -5.91M -40.1M -15.59M -203M -15.86M -15.52M -672M